Case Report |
Corresponding author: Kajetan Kiełbowski ( kajetan.kielbowski@onet.pl ) © 2023 Kajetan Kiełbowski, Piotr Ostrowski, Michał Kubisa, Jarosław Pieróg, Janusz Wójcik, Bartosz Kubisa.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Kiełbowski K, Ostrowski P, Kubisa M, Pieróg J, Wójcik J, Kubisa B (2023) Arterial sleeve lobectomy for lung cancer invading chest wall. Folia Medica 65(2): 311-315. https://doi.org/10.3897/folmed.65.e76253
|
Lung cancer is a leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is a predominant subtype and treatment may include immunotherapy, radiotherapy, chemotherapy, and surgery. Tumors of bigger size infiltrating large bronchi and vessels require more invasive resection such as pneumonectomy. To save lung parenchyma, sleeve lobectomy can be performed in certain patients.
We report the case of a patient with NSCLC infiltrating the chest wall who underwent arterial sleeve lobectomy with rib resection. Furthermore, we discuss other surgical treatment strategies.
A 58-year-old female patient was admitted to the hospital in 2020 with pain in her left posterolateral chest. Radiological imaging revealed a tumor (5.0×3.5×4.8 cm) in the top of the left lung, infiltrating pulmonary artery and ribs. Therefore, left upper sleeve lobectomy together with resection of rib blocks II to V was performed. The surgery was uncomplicated, but a few weeks postoperatively, the patient experienced repeated episodes of consciousness disturbances. Contrast CT revealed a cerebral malformation in the patient who died 3.5 months after surgery.
Sleeve lobectomy can be safely performed in patients with lung tumors infiltrating larger bronchi and vessels who would not tolerate pneumonectomy.
lung cancer, NSCLC, sleeve lobectomy
Lung cancer is the most common cause of cancer-related mortality with approximately 28% of men and 17% of women with cancer dying from the disease.[
in 2020, a 58-year-old Caucasian ex-smoker female with Hashimoto thyroiditis reported a pain in the left posterolateral part of the chest and was admitted to the Department of Thoracic Surgery and Transplantation of Pomeranian Medical University in Szczecin.
In the past, the patient had undergone two mastectomies (left-sided in 1999, right-sided in 2017) with bilateral breast reconstruction. Moreover, she was treated with post operational radio-, chemo- and hormone therapy. Physical examination and laboratory findings were within normal ranges. As part of the oncological follow-up, the patient underwent a chest computed tomography (CT). The examination found a tumor (5.0×3.5×4.8 cm) located at the top of the left lung and infiltrating the surrounding structures. According to the results of 18F-fluorodeoxyglucose positron emission tomography (PET), the lesion showed features of metabolic malignancy with standardized uptake value (SUV) of 11.1 (Fig.
Surgical treatment is the gold standard in early stages of NSCLC. The aim of surgical treatment is to completely remove tumorous tissues with adequate margin. Excision is considered when there is a high risk that a lesion is malignant or when the tumor presents features of metabolic malignancy in PET.[
Sleeve lobectomy is an accepted treatment for patients with T3N0 NSCLC, especially in patients that cannot tolerate pneumonectomy. This case is an example of thorough surgical resection with negative oncological margin using SL with chest wall resection. The death of this patient is considered as unrelated to underlying disease or treatment.